{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:04:44Z","timestamp":1761563084415,"version":"3.40.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002537"],"award-info":[{"award-number":["UL1TR002537"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["HHSN261201800012I\/HHSN26100001"],"award-info":[{"award-number":["HHSN261201800012I\/HHSN26100001"]}]},{"DOI":"10.13039\/100011343","name":"Holden Comprehensive Cancer Center, University of Iowa","doi-asserted-by":"publisher","award":["P30CA086862","Mezhir Award Grant CA244271"],"award-info":[{"award-number":["P30CA086862","Mezhir Award Grant CA244271"]}],"id":[{"id":"10.13039\/100011343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134524-RSG-20-017-01-CCE"],"award-info":[{"award-number":["134524-RSG-20-017-01-CCE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10552-024-01938-5","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T02:03:35Z","timestamp":1732586615000},"page":"433-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients"],"prefix":"10.1007","volume":"36","author":[{"given":"Breanna B.","family":"Greteman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison M.","family":"Wahlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa L.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"unstructured":"American Cancer Society. Cancer Statistics Center. https:\/\/cancerstatisticscenter.cancer.org\/?_ga=2.195481579.694263866.1673286093-884167040.1673286093#!\/","key":"1938_CR1"},{"issue":"3","key":"1938_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.16674","volume":"191","author":"\u00d8O Langseth","year":"2020","unstructured":"Langseth \u00d8O, Myklebust T\u00c5, Johannesen TB et al (2020) Incidence and survival of multiple myeloma: a population-based study of 10524 patients diagnosed 1982\u20132017. Br J Haematol 191(3):418\u2013425. https:\/\/doi.org\/10.1111\/bjh.16674","journal-title":"Br J Haematol"},{"unstructured":"American Cancer Society Multiple Myeloma: Survival Rates for Multiple Myeloma. https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/detection-diagnosis-staging\/survival-rates.html","key":"1938_CR3"},{"issue":"7","key":"1938_CR4","doi-asserted-by":"publisher","first-page":"e2116357","DOI":"10.1001\/jamanetworkopen.2021.16357","volume":"4","author":"K Bhattacharya","year":"2021","unstructured":"Bhattacharya K, Bentley JP, Ramachandran S et al (2021) Phase-specific and lifetime costs of multiple myeloma among older adults in the US. JAMA Netw Open 4(7):e2116357. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.16357","journal-title":"JAMA Netw Open"},{"unstructured":"American Cancer Society multiple myeloma: treatment options for multiple myeloma and other plasma cell disorders. https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/treating\/by-stage.html","key":"1938_CR5"},{"key":"1938_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S (2020) Multiple myeloma current treatment algorithms. Blood Cancer J 10. https:\/\/doi.org\/10.1038\/s41408-020-00359-2","journal-title":"Blood Cancer J 10"},{"issue":"6","key":"1938_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00277-023-05194-6","volume":"102","author":"K Doucette","year":"2023","unstructured":"Doucette K, Taylor AO, Chan B et al (2023) Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis. Ann Hematol 102(6):1443\u20131458. https:\/\/doi.org\/10.1007\/s00277-023-05194-6","journal-title":"Ann Hematol"},{"issue":"9","key":"1938_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.6004\/jnccn.2019.7298","volume":"17","author":"AT Freeman","year":"2019","unstructured":"Freeman AT, Kuo M, Zhou L et al (2019) Influence of  treating facility, provider volume, and patient-sharing on survival of patients with multiple myeloma. J Natl Compr Canc Netw 17(9):1100\u20131108. https:\/\/doi.org\/10.6004\/jnccn.2019.7298","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"1938_CR9","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1002\/cncr.32357","volume":"125","author":"RW Hsieh","year":"2019","unstructured":"Hsieh RW, Go RS, Abeykoon JP et al (2019) Characteristics of long-term survivors with multiple myeloma: a National Cancer Data Base analysis. Cancer 125(20):3574\u20133581. https:\/\/doi.org\/10.1002\/cncr.32357","journal-title":"Cancer"},{"issue":"12","key":"1938_CR10","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1002\/cam4.1246","volume":"6","author":"S Ailawadhi","year":"2017","unstructured":"Ailawadhi S, Frank RD, Advani P et al (2017) Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med 6(12):2876\u20132885","journal-title":"Cancer Med"},{"issue":"8","key":"1938_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/cncr.31237","volume":"124","author":"S Ailawadhi","year":"2018","unstructured":"Ailawadhi S, Frank RD, Sharma M et al (2018) Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities. Cancer 124(8):1710\u20131721","journal-title":"Cancer"},{"issue":"7","key":"1938_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","volume":"8","author":"S Ailawadhi","year":"2018","unstructured":"Ailawadhi S, Jacobus S, Sexton R et al (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8(7):67","journal-title":"Blood Cancer J"},{"key":"1938_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","volume":"62","author":"M Braunlin","year":"2021","unstructured":"Braunlin M, Belani R, Buchanan J et al (2021) Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011\u20132019 oncology clinic electronic health record data. Leuk Lymphoma 62:377\u2013386. https:\/\/doi.org\/10.1080\/10428194.2020.1827253","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1938_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.clml.2019.06.010","volume":"19","author":"S Ailawadhi","year":"2019","unstructured":"Ailawadhi S, Azzouqa AG, Hodge D et al (2019) Survival trends in young patients with multiple myeloma: a focus on racial-ethnic minorities. Clin Lymphoma Myeloma Leuk 19(10):619\u2013623","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1938_CR15","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/jgs.15534","volume":"66","author":"MM Marron","year":"2018","unstructured":"Marron MM, Ives DG, Boudreau RM et al (2018) Racial differences in cause-specific mortality between community-dwelling older Black and White adults. J Am Geriatr Soc 66(10):1980\u20131986","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"1938_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","volume":"12","author":"J Dong","year":"2022","unstructured":"Dong J, Garacci Z, Buradagunta CS et al (2022) Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J 12(2):34","journal-title":"Blood Cancer J"},{"issue":"9","key":"1938_CR17","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/cncr.30526","volume":"123","author":"MA Fiala","year":"2017","unstructured":"Fiala MA, Wildes TM (2017) Racial disparities in treatment use for multiple myeloma. Cancer 123(9):1590\u20131596","journal-title":"Cancer"},{"key":"1938_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.annepidem.2020.05.005","volume":"48","author":"GR Kamath","year":"2020","unstructured":"Kamath GR, Renteria AS, Jagannath S et al (2020) Where you live can impact your cancer risk: a look at multiple myeloma in New York City. Ann Epidemiol 48:43\u201350e44","journal-title":"Ann Epidemiol"},{"issue":"25","key":"1938_CR19","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"AJ Waxman","year":"2010","unstructured":"Waxman AJ, Mink PJ, Devesa SS et al (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116(25):5501\u20135506","journal-title":"Blood"},{"issue":"12","key":"1938_CR20","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1182\/bloodadvances.2021006652","volume":"6","author":"LC Peres","year":"2022","unstructured":"Peres LC, Colin-Leitzinger CM, Teng M et al (2022) Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv 6(12):3767\u20133778","journal-title":"Blood Adv"},{"issue":"20","key":"1938_CR21","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","volume":"3","author":"S Ailawadhi","year":"2019","unstructured":"Ailawadhi S, Parikh K, Abouzaid S et al (2019) Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv 3(20):2986\u20132994","journal-title":"Blood Adv"},{"issue":"13","key":"1938_CR22","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1080\/10428194.2021.1953012","volume":"62","author":"CC Fossum","year":"2021","unstructured":"Fossum CC, Navarro S, Farias AJ, Ballas LK (2021) Racial disparities in the use of palliative radiotherapy for black patients with multiple myeloma in the United States. Leuk Lymphoma 62(13):3235\u20133243","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1938_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","volume":"12","author":"J Dong","year":"2022","unstructured":"Dong J, Garacci Z, Buradagunta CS et al (2022) Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J 12(2):34. https:\/\/doi.org\/10.1038\/s41408-022-00633-5","journal-title":"Blood Cancer J"},{"issue":"4","key":"1938_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41408-022-00665-x","volume":"12","author":"K Maignan","year":"2022","unstructured":"Maignan K, Fashoyin-Aje LA, Torres AZ et al (2022) Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data. Blood Cancer J 12(4):65","journal-title":"Blood Cancer J"},{"issue":"1","key":"1938_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cncr.33208","volume":"127","author":"T Badar","year":"2021","unstructured":"Badar T, Hari P, D\u00e1vila O et al (2021) African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with whites in the United States. Cancer 127(1):82\u201392. https:\/\/doi.org\/10.1002\/cncr.33208","journal-title":"Cancer"},{"unstructured":"National Cancer Institute State Cancer Profiles. https:\/\/statecancerprofiles.cancer.gov\/index.html","key":"1938_CR26"},{"unstructured":"Surveillance Research Program National Cancer Institute SEER*Stat software (seer.cancer.gov\/seerstat) version 8.4.0","key":"1938_CR27"},{"issue":"9","key":"1938_CR28","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3109\/10428194.2015.1011156","volume":"56","author":"MA Fiala","year":"2015","unstructured":"Fiala MA, Finney JD, Liu J et al (2015) Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leuk Lymphoma 56(9):2643\u20132649. https:\/\/doi.org\/10.3109\/10428194.2015.1011156","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1938_CR29","doi-asserted-by":"publisher","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","volume":"109","author":"SH Chang","year":"2016","unstructured":"Chang SH, Luo S, Thomas TS et al (2016) Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study. J Natl Cancer Inst 109(5):djw264. https:\/\/doi.org\/10.1093\/jnci\/djw264","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1938_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/2643-3230.BCD-20-0123","volume":"2","author":"N Gormley","year":"2021","unstructured":"Gormley N, Fashoyin-Aje L, Locke T et al (2021) Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood Cancer Discov 2(2):119\u2013124. https:\/\/doi.org\/10.1158\/2643-3230.BCD-20-0123","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"1938_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","volume":"10","author":"BA Derman","year":"2020","unstructured":"Derman BA, Jasielec J, Langerman SS et al (2020) Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J 10(8):80. https:\/\/doi.org\/10.1038\/s41408-020-00347-6","journal-title":"Blood Cancer J"},{"issue":"1","key":"1938_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","volume":"23","author":"C Eisfeld","year":"2023","unstructured":"Eisfeld C, Kaj\u00fcter H, M\u00f6ller L et al (2023) Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. BMC Cancer 23(1):317. https:\/\/doi.org\/10.1186\/s12885-023-10787-5","journal-title":"BMC Cancer"},{"issue":"22","key":"1938_CR33","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113(22):5412\u20135417. https:\/\/doi.org\/10.1182\/blood-2008-12-194241","journal-title":"Blood"},{"issue":"22","key":"1938_CR34","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P et al (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113(22):5418\u20135422. https:\/\/doi.org\/10.1182\/blood-2008-12-195008","journal-title":"Blood"},{"issue":"8","key":"1938_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A et al (2024) Intergroupe francophone du my\u00e9lome, the Dutch-Belgian cooperative trial group for hematology oncology and the CASSIOPEIA investigators bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 25(8):1003\u20131014","journal-title":"Lancet Oncol"},{"key":"1938_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.17.00131","volume":"2","author":"PM Altrock","year":"2018","unstructured":"Altrock PM, Ferlic J, Galla T et al (2018) Computational model of progression to multiple myeloma identifies optimum screening strategies. JCO Clin Cancer Inf 2:1\u201312. https:\/\/doi.org\/10.1200\/CCI.17.00131","journal-title":"JCO Clin Cancer Inf"},{"issue":"11","key":"1938_CR37","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.3390\/ijms19113621","volume":"19","author":"MH Tomasson","year":"2018","unstructured":"Tomasson MH, Ali M, De Oliveira V et al (2018) Prevention is the best treatment: the case for understanding the transition from monoclonal gammopathy of undetermined significance to myeloma. Int J Mol Sci 19(11):3621. https:\/\/doi.org\/10.3390\/ijms19113621","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1938_CR38","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"1938_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amjmed.2022.08.030","volume":"136","author":"J Mikhael","year":"2023","unstructured":"Mikhael J, Bhutani M, Cole CE (2023) Multiple myeloma for the primary care provider: a practical review to promote earlier diagnosis among diverse populations. Am J Med 136(1):33\u201341","journal-title":"Am J Med"},{"issue":"5","key":"1938_CR40","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","volume":"9","author":"H El-Khoury","year":"2022","unstructured":"El-Khoury H, Lee DJ, Alberge JB et al (2022) Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol 9(5):e340\u2013e349. https:\/\/doi.org\/10.1016\/S2352-3026(22)00069-2","journal-title":"Lancet Haematol"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-024-01938-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-024-01938-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-024-01938-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:42:52Z","timestamp":1744206172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-024-01938-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1938"],"URL":"https:\/\/doi.org\/10.1007\/s10552-024-01938-5","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"type":"print","value":"0957-5243"},{"type":"electronic","value":"1573-7225"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"13 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BG, AK, MW, and MC have no conflicts of interest to disclose. MT receives support as PI for clinical trials from Pfizer and Janssen. MT and MB are CEO and CMO at LSF Medical Solutions. CS is the principal investigator of clinical trials from Janssen, Pfizer, Takeda, and Poseida pharmaceuticals and receives funding for work unrelated to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was deemed exempt from Institutional Review Board at the University of Iowa.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from participants and only deidentified data were analyzed for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\u00a0and publication"}}]}}